You have multiple options for MS care across Arizona, from major centers in Phoenix and Tucson to specialized regional clinics. Use this page to compare centers like Barrow Neurological Institute Multiple Sclerosis Center, Integrated Multiple Sclerosis Center, and University of Arizona Neuroimmunology so you can find the program and providers that fit your needs.
10 MS treatment centers18 active clinical trials13 providers with Medicare prescribing dataTop centers: Barrow, Integrated MS Center, University of Arizona
Center types in Arizona
Regional Neurology Group (3)
Academic MS Center (3)
Boutique MS Practice (2)
Dedicated MS Practice (2)
Filter by type:
Centers with Most Active Trials in Arizona
Ranked by active clinical trial count from ClinicalTrials.gov. Not a quality ranking.
3. 21st Century Neurology2 trials
Largest Care Teams in Arizona
1. Integrated Multiple Sclerosis Center6 providers
3. Center for Neurosciences3 providers
MS Care by City
Active MS clinical trials in Arizona
See all 26 MS trials in Arizona →ActivePhase 4
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
Novartis Pharmaceuticals
Chandler · Phoenix
ActivePhase 3
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Novartis Pharmaceuticals
Phoenix
ActivePhase 3
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
Novartis Pharmaceuticals
Phoenix · Phoenix · +1
ActivePhase 3
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Hoffmann-La Roche
Phoenix
ActivePhase 3
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
Novartis Pharmaceuticals
Phoenix
ActivePhase 3
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Novartis Pharmaceuticals
Phoenix · Tucson
ActivePhase 3
Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
Immunic AG
Phoenix




